newsfilter
← Latest News
GlobeNewswire·

Cara Therapeutics Reports Second Quarter 2022 Financial Results

– Net revenue was $23M for 2Q 2022 comprised of profit-sharing revenue of $8M from KORSUVA™ (difelikefalin) injection and a $15M milestone payment from the European Commission approval of Kapruvia® (difelikefalin) – – KOMFORT Phase 2